Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary R...

Descripción completa

Detalles Bibliográficos
Autores principales: Leite, Caio Abner, Carvalho, Raíssa Pierri, da Costa, Felipe Marques, Medeiros, Augusto Kreling, Schutz, Fabio Augusto, William, William Nassib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593413/
https://www.ncbi.nlm.nih.gov/pubmed/37876974
http://dx.doi.org/10.3389/fonc.2023.1264231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593413/
https://www.ncbi.nlm.nih.gov/pubmed/37876974
http://dx.doi.org/10.3389/fonc.2023.1264231

Ejemplares similares